Paliperidon Heumann
Long-Acting Injectable Atypical Antipsychotic – Paliperidone Palmitate Depot
Paliperidon Heumann is a long-acting injectable (LAI) atypical antipsychotic medicine containing paliperidone palmitate, the palmitate ester prodrug of paliperidone. It is administered as an intramuscular depot injection once every four weeks (after an initial loading phase) for the maintenance treatment of schizophrenia and schizoaffective disorder in adults whose symptoms have first been stabilized with oral paliperidone or risperidone. Paliperidone is the principal active metabolite of risperidone and acts primarily through balanced antagonism at dopamine D2 and serotonin 5-HT2A receptors. The depot formulation addresses the critical problem of medication non-adherence, which is a leading driver of psychotic relapse and hospitalization in schizophrenia.
Quick Facts: Paliperidon Heumann
Key Takeaways
- Paliperidon Heumann is a once-monthly intramuscular depot injection containing paliperidone palmitate, primarily used for the maintenance treatment of schizophrenia and schizoaffective disorder in adults.
- Paliperidone is the active metabolite of risperidone and works by blocking dopamine D2 and serotonin 5-HT2A receptors, reducing positive psychotic symptoms while helping to stabilize mood and cognition.
- Before starting the depot, patients must first tolerate an adequate trial of oral paliperidone or risperidone to confirm that no serious hypersensitivity or intolerance occurs.
- The most clinically important safety concerns include extrapyramidal symptoms, hyperprolactinemia, weight gain and metabolic changes, QT-interval prolongation, orthostatic hypotension and injection-site reactions.
- Paliperidon Heumann should never be used to treat acute agitation, is not approved for elderly patients with dementia-related psychosis, and requires close monitoring of weight, glucose, lipids and cardiovascular status throughout treatment.
What Is Paliperidon Heumann and What Is It Used For?
Paliperidone was first approved by the European Medicines Agency (EMA) in 2007 as an oral extended-release tablet (Invega) and the paliperidone palmitate long-acting injectable formulation (Xeplion in the EU, Invega Sustenna in the United States) received EU marketing authorization in 2011. Paliperidon Heumann is a generic version of paliperidone palmitate once-monthly depot manufactured by Heumann Pharma; it is therapeutically equivalent to the reference product and is used in the same clinical situations. Paliperidone itself is the principal active metabolite of risperidone, another widely used atypical antipsychotic. Because paliperidone is the 9-hydroxy metabolite of risperidone, patients who have previously tolerated risperidone will typically also tolerate paliperidone.
Schizophrenia is a chronic, severe, and disabling psychiatric disorder that affects approximately 24 million people worldwide according to the World Health Organization (WHO). It is characterized by a combination of positive symptoms (hallucinations, delusions, disorganized thinking and behavior), negative symptoms (blunted affect, social withdrawal, reduced motivation, anhedonia), and cognitive symptoms (impaired attention, working memory and executive function). Without effective long-term treatment, relapse rates are extremely high – roughly 80 percent within five years for patients who discontinue antipsychotic medication. Each relapse is associated with a greater risk of permanent functional decline, treatment resistance, and self-harm. Consequently, continuous and uninterrupted pharmacotherapy is the cornerstone of long-term management.
Long-acting injectable antipsychotics such as Paliperidon Heumann were developed specifically to address the problem of non-adherence to daily oral antipsychotics, which is estimated to affect at least 40 to 60 percent of patients at some point during their illness. Depot injections ensure that the medication has actually been delivered and provide steady plasma concentrations over weeks rather than hours, minimizing the peaks and troughs that can worsen side effects or allow symptoms to re-emerge. The approved indications for Paliperidon Heumann are:
- Maintenance treatment of schizophrenia in adults: Used in patients clinically stabilized with either oral paliperidone or oral risperidone. Long-term depot therapy is intended to prevent relapse and to allow patients to remain in the community rather than in hospital.
- Treatment of schizoaffective disorder in adults (in some jurisdictions): Schizoaffective disorder combines features of schizophrenia with persistent mood symptoms (mania, depression, or mixed states). Paliperidone palmitate once-monthly is approved in the EU for this indication as monotherapy or in combination with mood stabilizers or antidepressants.
- Patients with documented non-adherence to oral antipsychotics: Clinical guidelines from the National Institute for Health and Care Excellence (NICE) and the American Psychiatric Association (APA) recommend considering a long-acting injectable in patients who prefer this option, who have a history of non-adherence, or who have experienced multiple relapses.
Paliperidon Heumann is not appropriate for the rapid control of acute psychotic agitation because the depot preparation releases the drug slowly. For acute symptoms, an oral or short-acting intramuscular antipsychotic is used first, followed by transition to the depot once the patient is stable. Similarly, Paliperidon Heumann should not be considered a first-line option for patients who have never been exposed to paliperidone or risperidone; the oral trial is an essential safety step to detect hypersensitivity reactions before committing to a depot formulation that persists in the body for weeks.
Paliperidone is a potent antagonist of dopamine D2 receptors in the mesolimbic pathway, where excessive dopamine activity is believed to drive positive psychotic symptoms such as hallucinations and delusions. Its equally potent blockade of serotonin 5-HT2A receptors modulates cortical and nigrostriatal dopamine release, reducing the risk of extrapyramidal symptoms seen with older antipsychotics. Additional antagonism at alpha1- and alpha2-adrenergic receptors and at histamine H1 receptors contributes to some of its side effects, including orthostatic hypotension and mild sedation. Unlike clozapine, paliperidone has minimal affinity for muscarinic cholinergic receptors, which means that anticholinergic side effects such as dry mouth, urinary retention, and blurred vision are uncommon.
Paliperidone palmitate itself is a highly lipophilic prodrug designed specifically for slow dissolution from the intramuscular depot. After injection, the palmitate ester is gradually hydrolyzed by plasma esterases to release the active paliperidone moiety. This provides therapeutic plasma concentrations for approximately one month, eliminating the need for daily dosing. Steady-state concentrations are typically reached after three to four monthly injections, which is why clinicians often assess full treatment response only after 3 to 4 months of depot therapy.
What Should You Know Before Using Paliperidon Heumann?
Because Paliperidon Heumann is a long-acting depot that remains active in the body for weeks after the last injection, extra caution is required before the first dose is given. Any serious adverse reaction that develops after injection cannot be quickly reversed simply by stopping the medication, because plasma levels decline slowly over several months. For this reason, international guidelines universally recommend an initial oral trial of paliperidone or risperidone to confirm tolerability and allergy status.
Contraindications
You should not receive Paliperidon Heumann if any of the following apply to you:
- Known hypersensitivity to paliperidone, risperidone, or any of the excipients listed in the product information. Signs of hypersensitivity include rash, hives, swelling of the face, lips or tongue, angioedema, and anaphylactic reaction.
- No prior exposure to oral paliperidone or risperidone. An oral test run is mandatory unless previous tolerability has been clearly established.
- Dementia-related psychosis in elderly patients: paliperidone is not approved for this indication due to an increased risk of stroke and death.
Elderly patients with dementia-related psychosis treated with antipsychotic medications, including paliperidone palmitate, are at an increased risk of death. In pooled analyses of placebo-controlled trials, the death rate in drug-treated patients was approximately 1.6 to 1.7 times that of placebo. Cerebrovascular adverse events (stroke, transient ischemic attack), including fatalities, were reported at approximately three times the rate seen in placebo-treated patients. Paliperidon Heumann is not approved for the treatment of patients with dementia-related psychosis.
Warnings and Precautions
Before starting Paliperidon Heumann, inform your doctor if any of the following conditions apply to you, as they may require additional monitoring or careful balancing of risks and benefits:
- Cardiovascular disease or long QT syndrome: Paliperidone can cause QT-interval prolongation. The risk is higher in patients with congenital long QT syndrome, a family history of sudden cardiac death, or in those taking other QT-prolonging drugs. A baseline electrocardiogram (ECG) may be required.
- Diabetes or risk factors for metabolic syndrome: Paliperidone can cause hyperglycemia and, rarely, diabetic ketoacidosis. Regular monitoring of fasting glucose, HbA1c, lipid profile, and weight is strongly recommended before starting therapy and at intervals thereafter.
- Parkinson's disease or Lewy body dementia: Patients with these conditions are exceptionally sensitive to the extrapyramidal effects of antipsychotics and may develop severe worsening of parkinsonism or neuroleptic malignant syndrome.
- Seizure disorders: Paliperidone can lower the seizure threshold. Patients with epilepsy or brain injury need careful monitoring.
- Severe renal impairment: Paliperidone is primarily excreted by the kidneys. Dose adjustment is required in moderate renal impairment (creatinine clearance 50 to less than 80 ml/min), and the depot is not recommended in severe renal impairment (creatinine clearance below 50 ml/min).
- History of venous thromboembolism (VTE): Antipsychotic medicines as a class have been associated with increased risk of deep vein thrombosis and pulmonary embolism. Risk factors (immobilization, obesity, smoking, cancer, recent surgery) should be assessed.
- Hyperprolactinemia and hormone-sensitive conditions: Paliperidone produces sustained elevation of prolactin, which can cause galactorrhea, menstrual irregularities, sexual dysfunction, and potentially long-term bone density loss.
- Priapism: Rare but serious cases of prolonged painful erection have been reported. Patients should know to seek emergency help if an erection lasts more than four hours.
Neuroleptic malignant syndrome is a rare but potentially fatal reaction to antipsychotic medications. Symptoms include high fever, severe muscle stiffness, altered mental status, rapid heart rate, fluctuating blood pressure, and profuse sweating. Because Paliperidon Heumann has a long half-life, NMS may develop days or even weeks after an injection and can persist long after the drug is formally discontinued. Immediate medical attention is essential.
Pregnancy and Breastfeeding
Paliperidone should be used during pregnancy only when the benefits clearly outweigh the risks. Because the depot formulation remains pharmacologically active for several months after the last dose, any medication exposure extends well beyond the time of injection. Available epidemiological data do not demonstrate a consistent increase in major malformations, but the quality of the evidence is limited. Women of childbearing potential should use reliable contraception and discuss family planning with their psychiatrist before starting the depot.
Neonates exposed to antipsychotics during the third trimester of pregnancy are at risk of extrapyramidal and/or withdrawal symptoms after birth, which can vary in severity and duration. Reported symptoms include agitation, abnormal muscle tone (rigid or floppy), tremor, drowsiness, respiratory distress, and feeding difficulties. Neonates should be monitored closely, and mothers and healthcare teams should be aware of the possibility of neonatal intensive care unit (NICU) admission. Abrupt discontinuation of antipsychotic therapy during pregnancy should be avoided because relapse during pregnancy carries significant risks for both mother and child.
Paliperidone is excreted in small amounts in breast milk. Because of the potential for serious adverse reactions in nursing infants and the long half-life of the depot formulation, a decision should be made whether to discontinue breastfeeding or to switch to a different medication, taking into account the importance of treatment for the mother.
Driving and Operating Machinery
Paliperidon Heumann may cause drowsiness, dizziness, and visual disturbances, especially early in treatment or after dose adjustments. Patients should not drive or operate heavy machinery until they know how the medication affects them personally. Because the depot maintains stable plasma levels, patients who have already been on it for several months typically find that cognitive clarity improves compared with the variable levels seen with oral dosing.
How Does Paliperidon Heumann Interact with Other Drugs?
Paliperidone undergoes only limited hepatic metabolism; approximately 60 percent of an orally administered dose is excreted unchanged in the urine. The main metabolic pathways include dealkylation, hydroxylation, dehydrogenation, and benzisoxazole cleavage, with minor contributions from CYP2D6, CYP3A4 and P-glycoprotein. Consequently, paliperidone has relatively fewer pharmacokinetic interactions than many other atypical antipsychotics, but clinically significant pharmacodynamic interactions and a few important pharmacokinetic interactions still need attention.
Major Interactions
The following combinations are considered clinically significant and usually require dose adjustment, additional monitoring, or avoidance:
| Interacting Drug / Class | Effect | Clinical Recommendation |
|---|---|---|
| Strong CYP3A4 / P-gp inducers (carbamazepine, rifampicin, phenytoin, phenobarbital, St. John’s Wort) | Substantially decrease paliperidone plasma levels; risk of symptom recurrence | Reassess treatment when adding or removing an inducer; switching to an alternative antipsychotic may be preferred |
| QT-prolonging drugs (amiodarone, sotalol, quinidine, moxifloxacin, erythromycin, methadone, thioridazine) | Additive QT prolongation; increased risk of torsades de pointes | Avoid combination where possible; ECG monitoring and electrolyte correction (K+, Mg2+) are essential |
| Dopamine agonists and levodopa (for Parkinson’s disease) | Mutual antagonism; worsening of parkinsonian symptoms or reduced antipsychotic effect | Avoid the combination; if unavoidable, choose the lowest effective doses of both and monitor closely |
| CNS depressants (benzodiazepines, opioids, sedating antihistamines, alcohol, gabapentinoids) | Additive sedation, respiratory depression, falls, cognitive impairment | Use with caution; minimize concomitant doses and counsel about falls |
| Serotonergic drugs (SSRIs, SNRIs, tramadol, triptans, MAO inhibitors, St. John’s Wort) | Risk of serotonin syndrome in rare cases | Monitor for agitation, fever, clonus, hyperreflexia, diaphoresis and altered mental status |
| Antihypertensives | Enhanced blood-pressure-lowering effect; increased risk of orthostatic hypotension and falls | Check blood pressure when initiating therapy; adjust antihypertensive doses as needed |
| Medications that lower the seizure threshold (bupropion, tramadol, quinolone antibiotics, theophylline) | Additive reduction of seizure threshold; increased risk of convulsions | Use with caution in patients with a history of seizures; consider alternatives where available |
Other Notable Interactions
Several additional medications and substances warrant clinical awareness, even if they are not always classified as “major” interactions:
- Oral risperidone: Because paliperidone is the active metabolite of risperidone, concomitant use of oral risperidone with the paliperidone depot is usually redundant and may increase side effects. After initiation of Paliperidon Heumann, any ongoing oral risperidone treatment should be tapered according to the prescriber’s plan.
- Lithium: Co-administration with paliperidone is common in schizoaffective disorder. While generally safe, the combination can increase the risk of extrapyramidal symptoms and NMS, so careful monitoring is required.
- Valproate: Valproate can be used together with paliperidone, typically without clinically relevant pharmacokinetic interaction, though metabolic side effects such as weight gain may be additive.
- Methylphenidate and amphetamines: Stimulants may antagonize antipsychotic effects and, in some cases, destabilize psychosis.
- Metoclopramide and other dopamine blockers: Additive risk of extrapyramidal symptoms, tardive dyskinesia and NMS; avoid prolonged concomitant use.
- Grapefruit juice: Although paliperidone has limited CYP3A4 metabolism, large quantities of grapefruit juice should be avoided as a general precaution.
- Alcohol: Avoid or minimize alcohol intake due to additive CNS depression and worsening of the underlying psychiatric condition.
Because paliperidone relies only marginally on CYP2D6 metabolism (most of it is eliminated unchanged via the kidneys), the CYP2D6 poor-metabolizer phenotype has a smaller impact on paliperidone than on risperidone. This is one reason some clinicians favor paliperidone for patients with known CYP2D6 polymorphisms or complex pharmacogenetic profiles. Still, renal function is the most important clinical determinant of drug clearance and should be checked before and during long-term therapy.
What Is the Correct Dosage of Paliperidon Heumann?
Paliperidon Heumann is administered only by a healthcare professional in a clinical setting. The syringe should be shaken vigorously for at least 10 seconds immediately before use to ensure a homogeneous suspension. The injection site alternates between the right and left deltoid (or gluteal) muscles, and a proper intramuscular technique is essential to avoid inadvertent subcutaneous or intravascular administration. Dosing regimens vary by jurisdiction and clinical indication, but the principles outlined below are broadly consistent with the European Medicines Agency Summary of Product Characteristics (SmPC) and the FDA prescribing information.
Adults with Schizophrenia
| Phase | Dose | Interval | Injection Site |
|---|---|---|---|
| Initiation – Day 1 | 150 mg | Single loading dose | Deltoid muscle |
| Initiation – Day 8 | 100 mg | One week after day 1 (±2 days) | Deltoid muscle |
| Maintenance – usual | 75 mg (range 25–150 mg) | Every 4 weeks (±7 days) | Deltoid or gluteal muscle |
| Dose titration | Adjust by 25–75 mg increments | No more often than monthly | Based on tolerability and response |
A single 25 mg injection, such as the strength supplied by Paliperidon Heumann, is typically used either as a low maintenance dose in patients who are particularly sensitive, in those with moderate renal impairment (creatinine clearance 50 to less than 80 ml/min), or during a gradual dose reduction. It is not used for initiation. For patients switching from oral paliperidone or oral risperidone, the clinician will map the oral dose to an equivalent depot dose, with common conversions of 6 mg/day oral paliperidone to approximately 75 mg depot monthly.
Renal Impairment
Paliperidone is primarily renally eliminated, so dose adjustment is required when kidney function is reduced. In mild renal impairment (CrCl 50 to less than 80 ml/min), initiation should be with 100 mg on day 1 and 75 mg on day 8, followed by 50 mg monthly. Paliperidon Heumann is not recommended in severe renal impairment (CrCl below 50 ml/min).
Hepatic Impairment
Paliperidone undergoes minimal hepatic metabolism, so no dose adjustment is required in mild or moderate hepatic impairment. In severe hepatic impairment the evidence is limited; the drug has not been extensively studied and should be used with caution.
Children and Adolescents
Paliperidone palmitate once-monthly is approved in some jurisdictions for adolescents with schizophrenia starting at age 12 years (e.g. FDA), but is generally not recommended for use in children below this age. Dosing in adolescents is weight-based, and treatment should be supervised by a specialist in child and adolescent psychiatry. Paliperidon Heumann specifically is typically licensed for adults only; refer to the official product information for age limits in your country.
Elderly Patients
In elderly patients with normal renal function, no specific dose adjustment is required. However, elderly patients often have age-related decline in renal function, so the dose should be chosen based on creatinine clearance rather than serum creatinine alone. As noted earlier, paliperidone is not indicated for elderly patients with dementia-related psychosis because of the increased risk of death and cerebrovascular events.
Missed or Delayed Injection
Because Paliperidon Heumann is administered once every four weeks, a missed injection has more significant consequences than a missed oral dose. If the second initiation dose (planned for day 8) is missed, the timing of the next injection depends on how much time has elapsed since the first dose. If it is less than 4 weeks, the missed dose should be given as soon as possible; if it has been 4 to 7 weeks, re-initiation may be needed. For missed maintenance doses, the general principles are:
- Less than 6 weeks since last injection: Administer the maintenance dose as soon as possible and resume the monthly schedule.
- 6 weeks to 6 months since last injection: Re-initiate with two deltoid injections a week apart, then resume monthly maintenance dosing.
- More than 6 months since last injection: Treatment should be re-started as if it were a first initiation, with the full 150 mg / 100 mg deltoid loading regimen followed by maintenance.
Overdose
Because Paliperidon Heumann is administered by a healthcare professional, accidental overdose is rare. If an overdose does occur, seek emergency care immediately. Symptoms may include drowsiness, sedation, tachycardia, hypotension, QT prolongation, extrapyramidal symptoms, arrhythmias, seizures, and coma. Because the depot continues to release drug for weeks, overdose effects can persist or even worsen for days after presentation.
There is no specific antidote for paliperidone overdose. Management is supportive, with immediate establishment of a clear airway, ensuring adequate oxygenation and ventilation, continuous cardiac monitoring for arrhythmias, and correction of electrolyte abnormalities. Gastric lavage and activated charcoal are of limited value because the drug has already been injected intramuscularly. Hypotension should be treated with intravenous fluids and, if necessary, with sympathomimetics avoiding those with beta-agonist activity (because beta-adrenergic stimulation may worsen hypotension in the presence of alpha-blockade). Anticholinergic agents may be used for severe extrapyramidal reactions.
What Are the Side Effects of Paliperidon Heumann?
Like all antipsychotics, Paliperidon Heumann can cause side effects, although not every patient will experience them. Because the depot releases drug slowly and the active substance persists for weeks, any side effect may develop gradually and may take longer to resolve than with an oral medication. The risks and benefits of continued treatment should be reassessed periodically with your psychiatrist.
The frequencies below are grouped using the MedDRA convention also adopted by the European Medicines Agency: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), and frequency not known (reported in post-marketing surveillance).
Very Common
May affect more than 1 in 10 people
- Injection-site reactions (pain, induration, erythema)
- Insomnia
- Headache
- Upper respiratory tract infection (e.g. common cold)
Common
May affect up to 1 in 10 people
- Weight gain
- Increased appetite
- Anxiety and agitation
- Akathisia (inner restlessness)
- Extrapyramidal symptoms (tremor, muscle stiffness, cogwheel rigidity, dystonia)
- Somnolence and sedation
- Dizziness
- Tachycardia and palpitations
- Orthostatic hypotension
- Dry mouth, nausea, vomiting, constipation or diarrhea
- Dyspepsia
- Back pain and musculoskeletal discomfort
- Elevated prolactin and associated symptoms (galactorrhea, amenorrhea, gynecomastia, sexual dysfunction)
- Cough
- Blurred vision
- Fatigue
Uncommon
May affect up to 1 in 100 people
- Hyperglycemia, impaired glucose tolerance and new-onset type 2 diabetes
- Increased cholesterol and triglycerides
- Tardive dyskinesia (uncontrollable movements of the mouth, tongue, face and limbs)
- Seizures
- Syncope (fainting)
- QT-interval prolongation on ECG
- Heart rhythm abnormalities
- Atrioventricular block
- Peripheral edema
- Menstrual disturbances
- Erectile dysfunction and ejaculation disorders
- Breast discharge (galactorrhea) in both women and men
- Urinary incontinence or retention
- Nasal congestion
- Rash and skin reactions
- Dysphagia
Rare / Very Rare / Frequency Not Known
Includes post-marketing reports
- Neuroleptic malignant syndrome (NMS): high fever, severe rigidity, altered mental status, rapid heart rate, autonomic instability
- Diabetic ketoacidosis and severe hyperglycemic events
- Torsades de pointes and ventricular arrhythmias
- Sudden cardiac death
- Anaphylactic reaction and angioedema
- Agranulocytosis, neutropenia and leukopenia
- Thrombocytopenia
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism)
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH) with hyponatremia
- Water intoxication
- Priapism (prolonged, painful erection requiring urgent treatment)
- Rhabdomyolysis
- Severe cutaneous adverse reactions (Stevens-Johnson syndrome, DRESS)
- Intestinal obstruction, ileus and aspiration pneumonia
- Jaundice and liver injury
- Acute pancreatitis
- Hypothermia
- Embolic and thrombotic events
- Floppy iris syndrome during cataract surgery
- Neonatal drug withdrawal syndrome
Contact emergency services or your doctor urgently if you experience: high fever with muscle rigidity, sweating, and altered consciousness (possible NMS); uncontrollable facial or body movements (possible tardive dyskinesia); fainting or palpitations (possible arrhythmia); chest pain or shortness of breath (possible pulmonary embolism); extreme thirst with frequent urination and confusion (possible diabetic ketoacidosis); prolonged painful erection (priapism); severe allergic reactions with swelling of the face, lips, or throat; or any new thoughts of self-harm.
Injection-site reactions deserve special mention because they are a feature of all long-acting depot antipsychotics. Most reactions are mild pain, swelling, or bruising at the injection site that resolve within a few days. More severe nodular reactions, abscess formation, or persistent discomfort occur in a small minority and should be reported so that the injection site or technique can be adjusted. Rotation between the left and right deltoid or gluteal muscles reduces the risk of cumulative local reactions.
Reporting suspected adverse reactions after authorization of the medicinal product is an important part of ongoing pharmacovigilance. Healthcare professionals and patients are encouraged to report any suspected adverse reaction to their national reporting system, such as the United Kingdom Yellow Card Scheme, the European EudraVigilance database, or the United States MedWatch program.
How Should Paliperidon Heumann Be Stored?
Because Paliperidon Heumann is a sterile suspension for injection administered exclusively by a qualified healthcare professional, storage is usually handled by the clinic, hospital pharmacy or community pharmacy rather than the patient. However, if a dose is dispensed for administration at a home-visit or domiciliary setting, the following storage rules apply:
- Temperature: Store below 30°C (86°F), at controlled room temperature. Do not refrigerate and do not freeze, because freezing may damage the suspension.
- Light protection: Keep the pre-filled syringe in its original carton until use to protect from light.
- Shelf life: Check the expiry date printed on the carton and syringe label. Do not use the product after the date shown.
- Shaking: Shake the syringe vigorously for at least 10 seconds immediately before administration to resuspend the particles. If a homogeneous suspension cannot be obtained, do not use the syringe.
- Visual inspection: Examine the suspension for foreign particles and discoloration after shaking. Do not use if particulates, cracking of the syringe or discoloration are observed.
- Single-use: Each pre-filled syringe is intended for single administration. Do not re-use a partially administered syringe or share syringes between patients.
- Safe disposal: Any unused suspension, empty syringe, and the needle must be disposed of in accordance with local regulations for medicinal waste and sharps. Never dispose of medicines via wastewater or household waste.
Patients receiving Paliperidon Heumann should keep a medication log that records the date of each injection, the anatomical site (right/left, deltoid/gluteal), the dose given, and any side effects noted after administration. This log is valuable for the prescribing psychiatrist, for shared decision-making, and for ensuring continuity of care if the patient travels or moves to a new clinic.
What Does Paliperidon Heumann Contain?
Paliperidon Heumann is a sterile aqueous suspension of paliperidone palmitate microcrystals. Paliperidone palmitate is a lipophilic prodrug; it is the palmitic acid ester of the 9-hydroxy metabolite of risperidone. Once injected into skeletal muscle, it dissolves slowly and is hydrolyzed by esterases in plasma to release the pharmacologically active paliperidone molecule. This slow dissolution is responsible for the long duration of action of the depot injection.
Active Substance
Each 25 mg pre-filled syringe contains paliperidone palmitate equivalent to 25 mg of paliperidone palmitate (corresponding to approximately 15.6 mg of paliperidone base). Other strengths in the product range may include 50 mg, 75 mg, 100 mg and 150 mg pre-filled syringes, depending on local availability.
Inactive Ingredients (Excipients)
The excipients used in paliperidone palmitate depot formulations are selected to keep the microcrystals in suspension and to maintain physiological pH and tonicity. Typical excipients include:
- Polysorbate 20 – wetting agent that helps keep microcrystals suspended.
- Polyethylene glycol 4000 – viscosity modifier.
- Citric acid monohydrate – buffering agent.
- Disodium hydrogen phosphate anhydrous – buffering agent.
- Sodium dihydrogen phosphate monohydrate – buffering agent.
- Sodium hydroxide – used for pH adjustment.
- Water for injections – vehicle.
Patients with hypersensitivity to any of the listed ingredients should not receive Paliperidon Heumann. Patients on low-sodium diets should be aware that the medicine contains small amounts of sodium per dose, which is generally considered negligible from a dietary perspective but should be noted in the context of total daily sodium intake. The medicine does not contain lactose, gluten, gelatin or animal-derived proteins.
Frequently Asked Questions About Paliperidon Heumann
Because Paliperidon Heumann is a long-acting depot injection, therapeutic plasma levels build up gradually over weeks rather than hours. After the initiation doses given in the deltoid muscle on day 1 (150 mg) and day 8 (100 mg), detectable effects often appear within the first week, but the full antipsychotic benefit typically takes 6 to 8 weeks to develop as steady-state drug concentrations are reached. Before starting the depot, tolerability to oral paliperidone or risperidone should already have been established, which means most switching patients experience a seamless transition from their previous therapy without loss of symptom control.
Yes, paliperidone can cause weight gain, although the effect is generally considered intermediate among atypical antipsychotics – less than olanzapine and clozapine, and comparable to risperidone (which is not surprising given that paliperidone is risperidone’s active metabolite). Clinical trials reported mean weight gains of 1 to 3 kilograms over 13 weeks for most patients, with a subset gaining significantly more. Weight gain tends to be more pronounced in adolescents, in patients with a lower baseline body mass index, and during the first several months of therapy. Regular monitoring of weight, waist circumference, fasting glucose, HbA1c and lipid profile is strongly recommended at baseline and every three to six months thereafter. Lifestyle interventions (diet, physical activity) are the first-line management strategy; in selected cases, switching to a more metabolically favorable antipsychotic or adding metformin may be considered.
Long-acting injectable antipsychotics were developed specifically for patients with schizophrenia who have difficulty remembering or consistently taking daily oral medication. Non-adherence to oral antipsychotics is a leading cause of relapse, rehospitalization, and worsening of illness, and it is unfortunately very common even in patients who wish to take their medication. A once-monthly depot injection guarantees that the medication is actually delivered as prescribed, reduces the stigma and daily reminder of pill-taking, and has been shown in many real-world studies to significantly reduce relapse rates and psychiatric hospital admissions compared with oral therapy. Many patients also report an improved quality of life once they no longer need to think about medication every day.
If you miss a monthly injection, contact your healthcare provider as soon as possible. The re-initiation schedule depends on how many weeks have passed since your last injection. If less than 6 weeks have elapsed, the missed dose can usually be given as soon as possible and the monthly cycle resumed. If 6 weeks to 6 months have passed, a re-initiation regimen with two deltoid doses one week apart may be required before returning to the usual monthly maintenance dose. If more than 6 months have passed, your doctor will typically restart treatment from the beginning with the full initiation regimen (150 mg on day 1 and 100 mg on day 8). Because paliperidone continues to release from the depot for several weeks after the last injection, short delays usually cause only minor fluctuations, but longer gaps substantially increase the risk of relapse.
Alcohol should be avoided or kept to an absolute minimum during treatment with Paliperidon Heumann. Both alcohol and paliperidone depress the central nervous system, and their combination can intensify drowsiness, dizziness, and impaired judgment. Alcohol may worsen the underlying psychiatric condition, increase the risk of orthostatic hypotension and falls, predispose to dehydration and seizures, and reduce treatment effectiveness. If you regularly drink alcohol or have a history of alcohol use disorder, discuss this openly with your doctor so that the appropriate support and treatment can be offered alongside your psychiatric care.
Paliperidone should only be used during pregnancy when the benefits clearly outweigh the risks. Because the depot formulation remains in the body for months, any medication exposure continues long after the last injection. Neonates exposed to antipsychotics during the third trimester may experience extrapyramidal symptoms and withdrawal signs after birth, including tremor, abnormal muscle tone, breathing and feeding difficulties, and agitation. These effects are usually self-limiting. Paliperidone passes into breast milk in small amounts, so breastfeeding is generally not recommended while taking the depot. Untreated psychosis during pregnancy also carries significant risks for both mother and baby, so the decision requires careful, individualized discussion with a psychiatrist, obstetrician, and the patient.
Never stop Paliperidon Heumann without medical supervision. Because the medication is a depot formulation, plasma concentrations decline slowly over several months after the last injection, which provides a natural taper. However, stopping suddenly still carries a significant risk of relapse, especially in the first six months after discontinuation. Your psychiatrist will decide whether it is appropriate to continue indefinitely, switch to another antipsychotic, or gradually reduce the dose. Close monitoring for early warning signs of relapse (sleep changes, social withdrawal, re-emerging suspiciousness, unusual thoughts) is essential during and after any reduction, and family members or carers should be informed so they can help watch for these changes.
References
- European Medicines Agency (EMA). Xeplion (paliperidone palmitate) – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu/en/medicines/human/EPAR/xeplion
- U.S. Food and Drug Administration (FDA). Invega Sustenna (paliperidone palmitate) Prescribing Information. Available at: www.accessdata.fda.gov
- World Health Organization (WHO). Schizophrenia: Fact Sheet. Updated 2023. Available at: www.who.int/news-room/fact-sheets/detail/schizophrenia
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 2024.
- Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071. doi:10.1016/S0140-6736(12)60239-6
- Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117. doi:10.1016/j.schres.2009.10.026
- Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39-59. doi:10.1007/s40263-020-00779-5
- Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387-404. doi:10.1016/S2215-0366(21)00039-0
- De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126. doi:10.1038/nrendo.2011.156
- British National Formulary (BNF). Paliperidone. NICE Evidence Services. Updated 2025. Available at: bnf.nice.org.uk/drugs/paliperidone
- American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia, 3rd Edition. 2021. Available at: psychiatryonline.org
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Psychiatry and Clinical Pharmacology with documented academic background and clinical experience in long-acting injectable antipsychotics.
Medical Review
iMedic Medical Review Board – Independent panel of physicians who verify medical accuracy, evidence quality, and adherence to international guidelines (WHO, EMA, FDA, NICE, BNF).
Evidence Standard
Level 1A evidence based on systematic reviews, meta-analyses, and randomized controlled trials. GRADE evidence framework applied. No commercial funding.
Accessibility
Content reviewed for WCAG 2.2 Level AAA compliance. Optimized for screen readers, keyboard navigation, and assistive technology. High contrast and reduced-motion support enabled.
Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.